Model N Acquires Kalderos for Pharma Revenue Optimization

Model N, a significant player in revenue optimization for the life sciences sector, has strategically acquired Kalderos, a specialist in gross-to-net revenue intelligence. This move significantly enhances Model N's existing suite of solutions, particularly strengthening its capabilities in managing the complex U.S. pharmaceutical 340B drug discount program and refining gross-to-net revenue reconciliation for its extensive client base.

The acquisition integrates Kalderos' proprietary Truzo platform, which offers real-time, claims-level data visibility across various drug discount initiatives. This capability is crucial for pharmaceutical manufacturers navigating the intricate web of pricing regulations, rebate obligations, and the increasing demand for granular data scrutiny. By incorporating Kalderos' technology, Model N aims to provide its clients with a more proactive and precise approach to identifying and rectifying discrepancies, thereby minimizing revenue leakage within the pharmaceutical value chain.

The 340B program, a cornerstone of U.S. healthcare policy, mandates that drug makers offer discounted prices to eligible safety-net providers. This program represents a substantial and growing segment of the overall gross-to-net revenue landscape. With ongoing Medicare drug price negotiations and evolving pricing models, manufacturers face heightened pressure to ensure compliance and optimize revenue. The integration of Kalderos' expertise directly addresses these challenges, offering a unified solution for managing these complex rebate and discount programs.

Model N, which currently manages an impressive $1.3 trillion in gross revenue for its pharmaceutical and medical technology customers, sees this acquisition as a key step in its advanced analytics strategy. The addition of Kalderos' data assets will provide manufacturers with a more comprehensive view of their revenue lifecycle, from initial contracting through to final payment reconciliation. This deeper insight is expected to empower more informed decision-making and improve overall revenue performance.

The integration is anticipated to create a seamless workflow, connecting contracting processes, claims validation, dispute resolution, and payment systems. This synergy is particularly valuable as the pharmaceutical industry graves with increasing regulatory scrutiny and the need for greater transparency in drug pricing. Model N's recent launch of Data nSights, an AI-ready data and analytics solution, further underscores its commitment to leveraging advanced technology for revenue management.

Kalderos, previously advised by J.P. Morgan Securities as its exclusive financial advisor and Cooley for legal counsel, will now benefit from Model N's established scale, extensive customer relationships, and robust commercial infrastructure. Model N received legal counsel from Kirkland & Ellis for this transaction. The combined entity is positioned to offer a best-in-class, end-to-end commercialization and revenue optimization platform, solidifying its leadership in the life sciences software market.